AR076388A1 - Procedimientos para mejorar la farmocinetica - Google Patents
Procedimientos para mejorar la farmocineticaInfo
- Publication number
- AR076388A1 AR076388A1 ARP100101352A ARP100101352A AR076388A1 AR 076388 A1 AR076388 A1 AR 076388A1 AR P100101352 A ARP100101352 A AR P100101352A AR P100101352 A ARP100101352 A AR P100101352A AR 076388 A1 AR076388 A1 AR 076388A1
- Authority
- AR
- Argentina
- Prior art keywords
- cytochrome
- inhibitor
- formula
- compound
- monooxygenase
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 abstract 7
- 230000036765 blood level Effects 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 abstract 2
- 238000011260 co-administration Methods 0.000 abstract 2
- 108700012707 hepatitis C virus NS3 Proteins 0.000 abstract 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 2
- 229960000311 ritonavir Drugs 0.000 abstract 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940122280 Cytochrome P450 inhibitor Drugs 0.000 abstract 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 abstract 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
El objeto de la presente es el de elevar los niveles en sangre de un compuesto de la formula 1, mediante la co-administracion con un inhibidor del citocromo P450. Reivindicacion 1: Un procedimiento para incrementar la biodisponibilidad de un inhibidor de proteasa NS3/4A del virus de la hepatitis C, segun la formula 1, en un paciente, que comprende la co-administracion, al paciente, de un compuesto de la formula 1 y de un inhibidor de monooxigenasa del citocromo P450, en donde, el inhibidor de monooxigenasa, se encuentra presente en una cantidad suficiente como para levar los niveles en sangre de 1. Reivindicacion 2: Un procedimiento, segun la reivindicacion 1, en donde, el inhibidor de monooxigenasa del citocromo P450, es ritonavir. Reivindicacion 3: El procedimiento, segun la reivindicacion 2, en donde, el compuesto de la formula 1 y el ritonavir, se encuentran en formas separadas de dosificacion. Reivindicacion 15: Una composicion farmacéutica, que comprende un compuesto de la formula 1, o una base libre u otra sal farmacéuticamente aceptable de éste, y un inhibidor de monooxigenasa del citocromo P450 o una sal de éste farmacéuticamente aceptable, y por lo menos un excipiente, diluyente o vehículo (soporte), farmacéuticamente aceptable. El uso de R7227 y de un inhibidor de monooxigenasa del citocromo P450, en donde, la cantidad del inhibidor de monooxigenasa del citocromo P450, es suficiente, como para elevar los niveles en sangre del P7227, en comparacion con los niveles en sangre del R7227, en ausencia de un inhibidor de monooxigenasa del citocromo P450, para incrementar la biodisponibilidad de un inhibidor de NS3/4A-proteasa del virus de la hepatitis C, consistente en el R7227.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17272209P | 2009-04-25 | 2009-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076388A1 true AR076388A1 (es) | 2011-06-08 |
Family
ID=42236685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101352A AR076388A1 (es) | 2009-04-25 | 2010-04-23 | Procedimientos para mejorar la farmocinetica |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US20100272682A1 (es) |
| EP (1) | EP2421527B1 (es) |
| JP (1) | JP5523552B2 (es) |
| KR (1) | KR101471238B1 (es) |
| CN (2) | CN105233249A (es) |
| AR (1) | AR076388A1 (es) |
| AU (1) | AU2010240893B2 (es) |
| BR (1) | BRPI1015147B1 (es) |
| CA (1) | CA2758644C (es) |
| CL (1) | CL2011002643A1 (es) |
| CO (1) | CO6440593A2 (es) |
| CR (1) | CR20110551A (es) |
| DK (1) | DK2421527T3 (es) |
| EC (1) | ECSP11011420A (es) |
| ES (1) | ES2683736T3 (es) |
| HK (1) | HK1215858A1 (es) |
| HR (1) | HRP20181306T1 (es) |
| HU (1) | HUE040182T2 (es) |
| IL (1) | IL215620A (es) |
| LT (1) | LT2421527T (es) |
| MA (1) | MA33212B1 (es) |
| MX (2) | MX2011011105A (es) |
| MY (1) | MY169734A (es) |
| NZ (1) | NZ595917A (es) |
| PE (1) | PE20120638A1 (es) |
| PL (1) | PL2421527T3 (es) |
| PT (1) | PT2421527T (es) |
| RS (1) | RS57501B1 (es) |
| RU (1) | RU2591830C2 (es) |
| SG (1) | SG175328A1 (es) |
| SI (1) | SI2421527T1 (es) |
| TR (1) | TR201809600T4 (es) |
| TW (1) | TWI468160B (es) |
| UA (1) | UA103801C2 (es) |
| WO (1) | WO2010122087A1 (es) |
| ZA (1) | ZA201107421B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110075019A (ko) * | 2008-10-15 | 2011-07-05 | 인터뮨, 인크. | 치료용 항바이러스성 펩티드 |
| AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| EP2455068A1 (en) * | 2010-11-09 | 2012-05-23 | F. Hoffmann-La Roche AG | Pharmaceutical composition for treating HCV infections |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| EA201490837A1 (ru) | 2011-10-21 | 2014-11-28 | Эббви Инк. | Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| AU2013201532B2 (en) | 2011-10-21 | 2014-10-02 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| MX355102B (es) | 2012-01-11 | 2018-04-05 | Abbvie Ireland Unlimited Co | Procesos para hacer los inhibidores de la proteasa del hcv. |
| JP2015522022A (ja) * | 2012-06-27 | 2015-08-03 | アッヴィ・インコーポレイテッド | Ｈｃｖの処置に使用するためのａｂｔ−４５０およびリトナビルおよび例えばａｂｔ−０７２および／またはａｂｔ−３３３の併用処置 |
| BR112015007887A2 (pt) | 2012-10-08 | 2017-07-04 | Abbvie Inc | compostos úteis para produzir inibidores hcv protease |
| SI3137078T1 (sl) * | 2014-05-01 | 2019-08-30 | Eiger Biopharmaceuticals, Inc. | Zdravljenje okužbe s hepatitis delta virusom |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| CN107530338B (zh) | 2015-04-21 | 2020-12-01 | 艾格尔峰生物制药有限公司 | 包含洛那法尼和利托那韦的药物组合物 |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| CN117105928B (zh) * | 2023-08-22 | 2024-03-26 | 上海蓝木化工有限公司 | 一种蛋白酶抑制剂及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2189721T3 (es) | 1992-12-29 | 2003-07-16 | Abbott Lab | Inhibidores de proteasa retroviral. |
| IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
| US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| IL141438A0 (en) | 2000-02-23 | 2002-03-10 | Pfizer Prod Inc | Method of increasing the bioavailability and tissue penetration of azithromycin |
| US7169760B2 (en) * | 2000-07-21 | 2007-01-30 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| KR20050085681A (ko) | 2002-12-16 | 2005-08-29 | 베링거 인겔하임 인터내셔날 게엠베하 | 프로테아제 억제제와 같은 사이토크롬 ｐ450의 억제제와함께 비-뉴클레오시드 역전사효소 억제제(ｎｎｒｔｉ)를함유하는 배합물의 용도 |
| JP2007509950A (ja) * | 2003-10-27 | 2007-04-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｈｃｖ処置の組合せ剤 |
| US20080161324A1 (en) * | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
| US20120220520A1 (en) * | 2006-10-17 | 2012-08-30 | Van T Klooster Gerben Albert Eleutherius | Bioavailable combinations for hcv treatment |
-
2010
- 2010-04-22 ES ES10714883.5T patent/ES2683736T3/es active Active
- 2010-04-22 JP JP2012506491A patent/JP5523552B2/ja active Active
- 2010-04-22 MX MX2011011105A patent/MX2011011105A/es active IP Right Grant
- 2010-04-22 RS RS20180898A patent/RS57501B1/sr unknown
- 2010-04-22 HU HUE10714883A patent/HUE040182T2/hu unknown
- 2010-04-22 PL PL10714883T patent/PL2421527T3/pl unknown
- 2010-04-22 CN CN201510706536.XA patent/CN105233249A/zh active Pending
- 2010-04-22 SI SI201031725T patent/SI2421527T1/sl unknown
- 2010-04-22 PE PE2011001850A patent/PE20120638A1/es active IP Right Grant
- 2010-04-22 RU RU2011142651/15A patent/RU2591830C2/ru active
- 2010-04-22 KR KR1020117027997A patent/KR101471238B1/ko active Active
- 2010-04-22 DK DK10714883.5T patent/DK2421527T3/en active
- 2010-04-22 MY MYPI2011005073A patent/MY169734A/en unknown
- 2010-04-22 HR HRP20181306TT patent/HRP20181306T1/hr unknown
- 2010-04-22 EP EP10714883.5A patent/EP2421527B1/en active Active
- 2010-04-22 BR BRPI1015147-8A patent/BRPI1015147B1/pt active IP Right Grant
- 2010-04-22 MA MA34273A patent/MA33212B1/fr unknown
- 2010-04-22 CA CA2758644A patent/CA2758644C/en active Active
- 2010-04-22 UA UAA201113756A patent/UA103801C2/ru unknown
- 2010-04-22 NZ NZ595917A patent/NZ595917A/en unknown
- 2010-04-22 TW TW99112703A patent/TWI468160B/zh active
- 2010-04-22 TR TR2018/09600T patent/TR201809600T4/tr unknown
- 2010-04-22 SG SG2011077732A patent/SG175328A1/en unknown
- 2010-04-22 PT PT107148835T patent/PT2421527T/pt unknown
- 2010-04-22 LT LTEP10714883.5T patent/LT2421527T/lt unknown
- 2010-04-22 AU AU2010240893A patent/AU2010240893B2/en active Active
- 2010-04-22 MX MX2013013597A patent/MX351185B/es unknown
- 2010-04-22 CN CN2010800181204A patent/CN102413827A/zh active Pending
- 2010-04-22 WO PCT/EP2010/055317 patent/WO2010122087A1/en not_active Ceased
- 2010-04-23 US US12/766,051 patent/US20100272682A1/en not_active Abandoned
- 2010-04-23 AR ARP100101352A patent/AR076388A1/es not_active Application Discontinuation
-
2011
- 2011-10-06 IL IL215620A patent/IL215620A/en active IP Right Grant
- 2011-10-10 ZA ZA2011/07421A patent/ZA201107421B/en unknown
- 2011-10-12 CO CO11135691A patent/CO6440593A2/es active IP Right Grant
- 2011-10-19 CR CR20110551A patent/CR20110551A/es unknown
- 2011-10-24 CL CL2011002643A patent/CL2011002643A1/es unknown
- 2011-10-25 EC EC2011011420A patent/ECSP11011420A/es unknown
-
2016
- 2016-04-05 HK HK16103828.4A patent/HK1215858A1/zh unknown
-
2017
- 2017-01-12 US US15/404,398 patent/US20170119739A1/en not_active Abandoned
-
2018
- 2018-07-11 US US16/033,177 patent/US20180318267A1/en not_active Abandoned
-
2020
- 2020-04-08 US US16/842,855 patent/US10918626B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076388A1 (es) | Procedimientos para mejorar la farmocinetica | |
| DOP2019000218A (es) | Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas | |
| CL2012000919A1 (es) | Composicion que comprende un compuesto derivado de metoxicarbonil-amino-metilbutanoil-pirrolidinil-imidazol de formula i, inhibidor especifico de ns5a de hcv, y un compuesto derivado de oxo-pirrolidin-quinoleina de formula ii, inhibidor de proteasa ns3 de hcv; y uso en el tratamiento de la hepatitis c. | |
| UY32760A (es) | Composición farmacéutica para un inhibidor de proteasa del virus de la hepatitis c | |
| UY30437A1 (es) | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c | |
| NI201200139A (es) | Compuestos de sililo tricíclicos fusionados y métodos de uso de los mismos para el tratamiento de enfermedades virales. | |
| CO6280441A2 (es) | Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c | |
| UY30392A1 (es) | Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c | |
| CO6561788A2 (es) | Inhibidores del virus de la hepatitis c | |
| ECSP077648A (es) | Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c | |
| ECSP077649A (es) | Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c | |
| CL2012001449A1 (es) | Uso de combinaciones del compuesto n-[(ciclopentiloxi)carbonil]-3-metil-l-valiol-(4r)-4-({8-bromo-2-[2-(isobutirilamino)-1,3-tiazol-4-il]-7-metoxi-4-quinolinil}oxi)-n-[(1r,2s)-1-carboxi-2-vinilciclopropil]-l-prolinamida; y envase que comprende las formas de dosificacion. | |
| ECSP12012067A (es) | Inhibidores del virus de la hepatitis c | |
| UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
| CL2012001230A1 (es) | Compuestos derivados de biciclos, inhibidores de la proteina ns5a; composicion farmaceutica que los comprende; uso en el tratamiento de la hepatitis c. | |
| CO6501153A2 (es) | Inhibidores macrociclicos de serina proteasa | |
| UY31215A1 (es) | Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia. | |
| EA201270540A1 (ru) | Макроциклические ингибиторы интегразы | |
| ECSP10010636A (es) | El uso de partículas transportadoras sólidas para mejorar la procesabilidad de un agente farmacéutico | |
| UY30903A1 (es) | Nuevas sformas de sales de n-[2-(dietilamino)etil]-n-(2-{[2-(4-hidorxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7-il)etil]amino}etil)-3-[2-(1-naftil)etoxi]propanamida, composiciones comprendiéndolas, procesos de preparacion y aplicaciones. | |
| CL2008003267A1 (es) | Compuestos derivados de macrociclos fusionados con pirrolidina, inhibidores de la serina proteasa ns3; composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la hepatitis c. | |
| UY31685A (es) | Compuestos antivirales, composiciones y metodos para usarlos | |
| CL2013003229A1 (es) | Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc. | |
| ECSP13012791A (es) | Inhibidores de serina proteasa de hepatitis c a base de macrocíclicos de fenantridina | |
| CL2013000670A1 (es) | Metodo para tratar una infeccion por virus de la hepatitis c (hcv) que comprende admninistrar un inhibidor de la serina proteasa ns3 del hvc, un inhibidor de la arn polimerasa dependiente de arn ns5b de hcv y opcionalmente ribavirina; composicion farmaceutica; estuche; y su uso de para el tratamiento de una infeccion por hcv. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |